We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stands against other Billionaire Joseph Edelman’s long-term stock picks.
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing. As the founder, CEO, and portfolio manager of Perceptive Advisors, Edelman has built a reputation as one of the most successful and insightful investors in the biotech sector. His deep understanding of the scientific, clinical, and financial aspects of the industry has enabled him to identify promising companies and generate significant returns for his investors.
Joseph Edelman earned his Bachelor of Arts in Psychology from the University of California, San Diego, and later pursued an MBA from NYU Stern School of Business. He began his career as a biotechnology analyst at Prudential Securities and subsequently worked as a portfolio manager at Paramount Capital Asset Management. These early roles provided Edelman with a foundation in analyzing biotech companies, understanding their value drivers, and assessing the risks associated with drug development and regulatory approval processes.
Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs.
In 1999, Edelman founded Perceptive Advisors, a New York-based investment firm focused on the life sciences sector. The firm initially launched with a single hedge fund, the Perceptive Life Sciences Fund, and has since expanded to manage billions of dollars in assets. Perceptive Advisors specializes in identifying high-growth potential in emerging biotech, pharmaceutical, and healthcare companies, with an emphasis on innovation in areas such as gene therapy, oncology, and rare diseases. Under Edelman’s leadership, Perceptive Advisors has achieved remarkable success.
The firm manages over $4.7 billion in the 13F portfolio as of the end of the third quarter of 2024. The Perceptive Life Sciences Fund has delivered annualized returns exceeding 15% over the past two decades, far outpacing broader market indices. Edelman has been an early backer of biotech companies that went on to achieve significant breakthroughs, including Moderna and CRISPR Therapeutics. While Edelman’s track record is stellar, the biotech sector’s inherent risks mean that not all investments succeed. Regulatory setbacks, clinical trial failures, and market sentiment can lead to significant volatility.
Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities.
For this article, we selected stocks by combing through the 13F portfolio of Perceptive Advisors at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A medical researcher in a laboratory focusing on a diagnosis of an ocular disease.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)
Number of Hedge Fund Holders: 11
Perceptive Advisors’ Stake: $6.1 million
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated, autoimmune and metabolic diseases. The following factors make Aldeyra Therapeutics (NASDAQ:ALDX) a great investment opportunity. First, significant financial growth was seen, as illustrated in the report of the third quarter of 2024, highlighting $122.9 million in cash and cash equivalents. Secondly, innovative projects, like introducing Reproxalap, a new drug application for the treatment of dry eye disease, serve as a great milestone for the company. As per the recent news, the New Drug Application (NDA) for Reproxalap has been accepted for review by the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) date set for April 2025. Moreover, the company has expanded its pipeline into retinal diseases through the acquisition of Helio Vision, a company focused on developing therapies for retinal conditions. This initiative will diversify the company’s portfolio.
Overall, ALDX ranks 8th on our list of Billionaire Joseph Edelman’s long-term stock picks. While we acknowledge the potential of ALDX as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than ALDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.
